Amgen opposes Regeneron using Applied Medical’s win against Medtronic to back US case
( July 14, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Amgen opposed Regeneron citing Applied Medical’s antitrust win against Medtronic in support of its antitrust case against Amgen over cholesterol-reducing medication, arguing that the order is an out-of-circuit, highly fact-specific decision. Amgen said “while the Medtronic court believed a jury could have found up to 47% of sales foreclosed — within the ‘40% to 50%’ typically required in the Third Circuit — there is no case law that can support substantial foreclosure at 10-12%,” as in the case brought by Regeneron.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.